Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

TLRY vs ACB

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TLRY
Tilray Brands, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$671M
5Y Perf.-41.5%
ACB
Aurora Cannabis Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$201M
5Y Perf.-97.5%

TLRY vs ACB — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TLRY logoTLRY
ACB logoACB
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & Generic
Market Cap$671M$201M
Revenue (TTM)$1.17B$361M
Net Income (TTM)$-2.95B$41M
Gross Margin28.0%62.7%
Operating Margin-266.0%13.3%
Forward P/E168.8x
Total Debt$451M$104M
Cash & Equiv.$304M$184M

TLRY vs ACBLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TLRY
ACB
StockMay 20May 26Return
Tilray Brands, Inc. (TLRY)10058.5-41.5%
Aurora Cannabis Inc. (ACB)1002.5-97.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: TLRY vs ACB

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ACB leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Tilray Brands, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
TLRY
Tilray Brands, Inc.
The Long-Run Compounder

TLRY is the clearest fit if your priority is long-term compounding.

  • -74.3% 10Y total return vs ACB's -92.2%
  • +12.7% vs ACB's -23.2%
Best for: long-term compounding
ACB
Aurora Cannabis Inc.
The Income Pick

ACB carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 1.81
  • Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
  • Lower volatility, beta 1.81, Low D/E 17.2%, current ratio 4.31x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthACB logoACB27.0% revenue growth vs TLRY's 4.8%
Quality / MarginsACB logoACB11.2% margin vs TLRY's -252.6%
Stability / SafetyACB logoACBBeta 1.81 vs TLRY's 2.03, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)TLRY logoTLRY+12.7% vs ACB's -23.2%
Efficiency (ROA)ACB logoACB5.2% ROA vs TLRY's -100.6%, ROIC 0.7% vs -66.2%

TLRY vs ACB — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TLRYTilray Brands, Inc.
FY 2025
Cannabis Segment
36.1%$331M
Distribution Revenue
29.6%$271M
Beverage Alcohol Business
27.7%$253M
Wellness Business
6.6%$60M
ACBAurora Cannabis Inc.

Segment breakdown not available.

TLRY vs ACB — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLACBLAGGINGTLRY

Income & Cash Flow (Last 12 Months)

ACB leads this category, winning 4 of 6 comparable metrics.

TLRY is the larger business by revenue, generating $1.2B annually — 3.2x ACB's $361M. ACB is the more profitable business, keeping 11.2% of every revenue dollar as net income compared to TLRY's -2.5%. On growth, ACB holds the edge at +6.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTLRY logoTLRYTilray Brands, In…ACB logoACBAurora Cannabis I…
RevenueTrailing 12 months$1.2B$361M
EBITDAEarnings before interest/tax-$3.0B$71M
Net IncomeAfter-tax profit-$2.9B$41M
Free Cash FlowCash after capex-$94M-$31M
Gross MarginGross profit ÷ Revenue+28.0%+62.7%
Operating MarginEBIT ÷ Revenue-2.7%+13.3%
Net MarginNet income ÷ Revenue-2.5%+11.2%
FCF MarginFCF ÷ Revenue-8.1%-8.7%
Rev. Growth (YoY)Latest quarter vs prior year+3.0%+6.8%
EPS Growth (YoY)Latest quarter vs prior year+70.7%-94.5%
ACB leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

TLRY leads this category, winning 3 of 3 comparable metrics.
MetricTLRY logoTLRYTilray Brands, In…ACB logoACBAurora Cannabis I…
Market CapShares × price$671M$201M
Enterprise ValueMkt cap + debt − cash$818M$142M
Trailing P/EPrice ÷ TTM EPS-0.17x168.77x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple7.00x
Price / SalesMarket cap ÷ Revenue0.60x0.79x
Price / BookPrice ÷ Book value/share0.25x0.44x
Price / FCFMarket cap ÷ FCF
TLRY leads this category, winning 3 of 3 comparable metrics.

Profitability & Efficiency

ACB leads this category, winning 9 of 9 comparable metrics.

ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-137 for TLRY. ACB carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to TLRY's 0.22x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs TLRY's 4/9, reflecting strong financial health.

MetricTLRY logoTLRYTilray Brands, In…ACB logoACBAurora Cannabis I…
ROE (TTM)Return on equity-136.5%+7.2%
ROA (TTM)Return on assets-100.6%+5.2%
ROICReturn on invested capital-66.2%+0.7%
ROCEReturn on capital employed-78.1%+0.7%
Piotroski ScoreFundamental quality 0–947
Debt / EquityFinancial leverage0.22x0.17x
Net DebtTotal debt minus cash$147M-$80M
Cash & Equiv.Liquid assets$304M$184M
Total DebtShort + long-term debt$451M$104M
Interest CoverageEBIT ÷ Interest expense-89.43x6.27x
ACB leads this category, winning 9 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TLRY leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in TLRY five years ago would be worth $4,071 today (with dividends reinvested), compared to $418 for ACB. Over the past 12 months, TLRY leads with a +1268.2% total return vs ACB's -23.2%. The 3-year compound annual growth rate (CAGR) favors TLRY at 27.5% vs ACB's -18.3% — a key indicator of consistent wealth creation.

MetricTLRY logoTLRYTilray Brands, In…ACB logoACBAurora Cannabis I…
YTD ReturnYear-to-date-40.7%-18.4%
1-Year ReturnPast 12 months+1268.2%-23.2%
3-Year ReturnCumulative with dividends+107.2%-45.5%
5-Year ReturnCumulative with dividends-59.3%-95.8%
10-Year ReturnCumulative with dividends-74.3%-92.2%
CAGR (3Y)Annualised 3-year return+27.5%-18.3%
TLRY leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

ACB leads this category, winning 2 of 2 comparable metrics.

ACB is the less volatile stock with a 1.81 beta — it tends to amplify market swings less than TLRY's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACB currently trades 53.1% from its 52-week high vs TLRY's 36.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTLRY logoTLRYTilray Brands, In…ACB logoACBAurora Cannabis I…
Beta (5Y)Sensitivity to S&P 5002.03x1.81x
52-Week HighHighest price in past year$15.70$6.67
52-Week LowLowest price in past year$0.35$3.07
% of 52W HighCurrent price vs 52-week peak+36.7%+53.1%
RSI (14)Momentum oscillator 0–10036.748.7
Avg Volume (50D)Average daily shares traded4.6M975K
ACB leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates TLRY as "Hold" and ACB as "Hold". Consensus price targets imply 73.6% upside for TLRY (target: $10) vs 67.2% for ACB (target: $6).

MetricTLRY logoTLRYTilray Brands, In…ACB logoACBAurora Cannabis I…
Analyst RatingConsensus buy/hold/sellHoldHold
Price TargetConsensus 12-month target$10.00$5.92
# AnalystsCovering analysts2014
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ACB leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TLRY leads in 2 (Valuation Metrics, Total Returns).

Best OverallAurora Cannabis Inc. (ACB)Leads 3 of 6 categories
Loading custom metrics...

TLRY vs ACB: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is TLRY or ACB a better buy right now?

For growth investors, Aurora Cannabis Inc.

(ACB) is the stronger pick with 27. 0% revenue growth year-over-year, versus 4. 8% for Tilray Brands, Inc. (TLRY). Aurora Cannabis Inc. (ACB) offers the better valuation at 168. 8x trailing P/E, making it the more compelling value choice. Analysts rate Tilray Brands, Inc. (TLRY) a "Hold" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — TLRY or ACB?

Over the past 5 years, Tilray Brands, Inc.

(TLRY) delivered a total return of -59. 3%, compared to -95. 8% for Aurora Cannabis Inc. (ACB). Over 10 years, the gap is even starker: TLRY returned -74. 3% versus ACB's -92. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — TLRY or ACB?

By beta (market sensitivity over 5 years), Aurora Cannabis Inc.

(ACB) is the lower-risk stock at 1. 81β versus Tilray Brands, Inc. 's 2. 03β — meaning TLRY is approximately 12% more volatile than ACB relative to the S&P 500. On balance sheet safety, Aurora Cannabis Inc. (ACB) carries a lower debt/equity ratio of 17% versus 22% for Tilray Brands, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — TLRY or ACB?

By revenue growth (latest reported year), Aurora Cannabis Inc.

(ACB) is pulling ahead at 27. 0% versus 4. 8% for Tilray Brands, Inc. (TLRY). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, ACB leads at 15. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — TLRY or ACB?

Aurora Cannabis Inc.

(ACB) is the more profitable company, earning 0. 5% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps 0. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACB leads at 1. 4% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — ACB leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — TLRY or ACB?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is TLRY or ACB better for a retirement portfolio?

For long-horizon retirement investors, Aurora Cannabis Inc.

(ACB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACB: -92. 2%, TLRY: -74. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between TLRY and ACB?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TLRY is a small-cap quality compounder stock; ACB is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

TLRY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen
Stocks Like

ACB

Steady Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform TLRY and ACB on the metrics below

Revenue Growth>
%
(TLRY: 3.0% · ACB: 6.8%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.